226 related articles for article (PubMed ID: 24473850)
21. The fixed-dose combination drug for secondary cardiovascular prevention project: improving equitable access and adherence to secondary cardiovascular prevention with a fixed-dose combination drug. Study design and objectives.
Sanz G; Fuster V; Guzmán L; Guglietta A; Arnáiz JA; Martínez F; Sarria A; Roncaglioni MC; Taubert K
Am Heart J; 2011 Nov; 162(5):811-817.e1. PubMed ID: 22093195
[TBL] [Abstract][Full Text] [Related]
22. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
23. Primary prevention for cardiovascular diseases: can statins replace aspirin?
Abdul Hadi M; Ming LC; Awaisu A
Med Princ Pract; 2011; 20(6):584. PubMed ID: 21986022
[No Abstract] [Full Text] [Related]
24. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
Wojakowski W; Gmiński J
Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
[TBL] [Abstract][Full Text] [Related]
25. [Primary prevention of cardiovascular diseases with acetylsalicylic acid].
Waltering A; Hemkens L; Florack C
Dtsch Med Wochenschr; 2005 Dec; 130(49):2847-52. PubMed ID: 16317615
[TBL] [Abstract][Full Text] [Related]
26. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.
Ridker PM; Cook NR; Lee IM; Gordon D; Gaziano JM; Manson JE; Hennekens CH; Buring JE
N Engl J Med; 2005 Mar; 352(13):1293-304. PubMed ID: 15753114
[TBL] [Abstract][Full Text] [Related]
27. Aspirin for the prevention of cardiovascular morbidity.
Sanchez-Ross M; Waller AH; Maher J; Klapholz M; Haider B; Kaluski E
Minerva Med; 2010 Aug; 101(4):205-14. PubMed ID: 21030934
[TBL] [Abstract][Full Text] [Related]
28. The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) and the risk of vascular morbidity and mortality in patients with coronary artery disease.
Lafeber M; Spiering W; van der Graaf Y; Nathoe H; Bots ML; Grobbee DE; Visseren FL
Am Heart J; 2013 Aug; 166(2):282-289.e1. PubMed ID: 23895811
[TBL] [Abstract][Full Text] [Related]
29. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients.
Mills EJ; Rachlis B; Wu P; Devereaux PJ; Arora P; Perri D
J Am Coll Cardiol; 2008 Nov; 52(22):1769-81. PubMed ID: 19022156
[TBL] [Abstract][Full Text] [Related]
30. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
Lardizabal JA; Deedwania P
Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102
[TBL] [Abstract][Full Text] [Related]
31. Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease.
Gotto AM
Circulation; 2006 Sep; 114(12):1310-4; discussion 1314. PubMed ID: 16982952
[No Abstract] [Full Text] [Related]
32. Effect of statin adherence on cerebrovascular disease in primary prevention.
Perreault S; Ellia L; Dragomir A; Côté R; Blais L; Bérard A; Lalonde L
Am J Med; 2009 Jul; 122(7):647-55. PubMed ID: 19559167
[TBL] [Abstract][Full Text] [Related]
33. [Does statin therapy reduce the risk of stroke? A meta-analysis].
Sirol M; Bouzamondo A; Sanchez P; Lechat P
Ann Med Interne (Paris); 2001 Apr; 152(3):188-93. PubMed ID: 11431579
[TBL] [Abstract][Full Text] [Related]
34. Aspirin overprescription in primary cardiovascular prevention.
Manes C; Giacci L; Sciartilli A; D'Alleva A; De Caterina R
Thromb Res; 2006; 118(4):471-7. PubMed ID: 16321425
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of statin treatment based on cardiovascular outcomes in elderly patients: a standard meta-analysis and Bayesian network analysis.
Zhai C; Hou K; Li R; Hu Y; Zhang J; Zhang Y; Wang L; Zhang R; Cong H
J Int Med Res; 2020 Jun; 48(6):300060520926349. PubMed ID: 32529863
[TBL] [Abstract][Full Text] [Related]
36. Meta-Analyses of Statin Therapy for Primary Prevention Do Not Answer Key Questions: An Empirical Appraisal of 5 Years of Statin Meta-Analyses.
Huded C; Prasad V
Am J Cardiovasc Drugs; 2015 Dec; 15(6):379-86. PubMed ID: 26141958
[TBL] [Abstract][Full Text] [Related]
37. Impact of the additive effect of angiotensin-converting enzyme inhibitors and /or statins with antiplatelet medication on mortality after acute ischaemic stroke.
Hassan Y; Al-Jabi SW; Aziz NA; Looi I; Zyoud SH
Basic Clin Pharmacol Toxicol; 2012 Apr; 110(4):370-7. PubMed ID: 22023326
[TBL] [Abstract][Full Text] [Related]
38. Do aspirin and statins prevent severe sepsis?
Sanchez MA; Thomas CB; O'Neal HR
Curr Opin Infect Dis; 2012 Jun; 25(3):345-50. PubMed ID: 22395760
[TBL] [Abstract][Full Text] [Related]
39. The Polypill in the prevention of cardiovascular disease.
Wald DS; Wald NJ
Prev Med; 2011 Jan; 52(1):16-7. PubMed ID: 21130112
[No Abstract] [Full Text] [Related]
40. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
